Bispecific antigen binding molecule for a costimulatory TNF receptor
The invention relates to bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to epithelial cell adhesion molecule (EpCAM), and to methods of producing these molecules and to methods of using the same.
1. A bispecific antigen binding molecule, comprising
(a) at least one moiety that specifically binds to OX40 comprising an antibody light chain variable region (VL) comprising: (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:15, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:18, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:22; and an antibody heavy chain variable region (VH) comprising: (iv) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:4, (v) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:6, and (vi) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:9, and
(b) at least one moiety that specifically binds to epithelial cell adhesion molecule (EpCAM) comprising an antibody light chain variable region (VL) comprising: (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:54, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:55, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 56; and an antibody heavy chain variable region (VH) comprising: (iv) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:51, (v) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:52, and (vi) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:53.
2. The bispecific antigen binding molecule of claim 1 , additionally comprising (c) a Fc region composed of a first subunit and a second subunit that form stable association.
3. The bispecific antigen binding molecule of claim 2 , wherein the Fc region is of human IgG1 subclass with the amino acid mutations L234A, L235A and P329G, wherein the amino acid numbering is according to Kabat EU index.
4. The bispecific antibody of claim 2 , wherein
(i) the first subunit of the Fc region comprises the amino acid substitutions S354C and T366W and the second subunit of the Fc region comprises the amino acid substitutions Y349C, T366S and Y407V, wherein the amino acid numbering is according to Kabat EU index, or
(ii) the first subunit of the Fc region comprises the amino acid substitutions K392D and K409D and the second subunit of the Fc region comprises the amino acid substitutions E356K and D399K, wherein the amino acid numbering is according to Kabat EU index.
5. The bispecific antigen binding molecule of claim 1 , wherein the moiety that specifically binds to OX40 binds to a polypeptide comprising, the amino acid sequence of SEQ ID NO:1, and wherein the moiety that specifically binds to EpCAM binds to a polypeptide comprising, the amino acid sequence of SEQ ID NO:49.
6. The bispecific antigen binding molecule of claim 1 , wherein the moiety that specifically binds to OX40 comprises
a VH comprising the amino acid sequence of SEQ ID NO:35 and a VL comprising the amino acid sequence of SEQ ID NO:36.
7. The bispecific antigen binding molecule of claim 1 , comprising
(i) at least one moiety that specifically binds to OX40, comprising a VH comprising the amino acid sequence of SEQ ID NO: 35 and a VL comprising the amino acid sequence of SEQ ID NO: 36, and
(ii) at least one moiety that specifically binds to EpCAM, comprising a VH comprising the amino acid sequence of SEQ ID NO:63 and a VL comprising the amino acid sequence of SEQ ID NO: 64.
8. A pharmaceutical composition comprising the bispecific antigen binding molecule of claim 1 , and at least one pharmaceutically acceptable excipient.
9. A bispecific antigen binding molecule that specifically binds to OX40 and EpCAM comprising:
a first heavy chain comprising the amino acid sequence of SEQ ID NO:183,
a second heavy chain comprising the amino acid sequence of SEQ ID NO:184, and
four light chains, each comprising the amino acid sequence of SEQ ID NO:182.